Last reviewed · How we verify
FOLFOX/ FOLFIRI with panitumumab
This combination uses chemotherapy (FOLFOX or FOLFIRI) to kill rapidly dividing cancer cells, while panitumumab blocks EGFR signaling to prevent tumor growth and enhance chemotherapy efficacy.
This combination uses chemotherapy (FOLFOX or FOLFIRI) to kill rapidly dividing cancer cells, while panitumumab blocks EGFR signaling to prevent tumor growth and enhance chemotherapy efficacy. Used for Metastatic colorectal cancer, KRAS wild-type.
At a glance
| Generic name | FOLFOX/ FOLFIRI with panitumumab |
|---|---|
| Also known as | - panitumumab, - irinotecan, - leucovorin, - 5-fluorouracil, - oxaliplatin |
| Sponsor | Dutch Colorectal Cancer Group |
| Drug class | Chemotherapy combination with EGFR inhibitor |
| Target | EGFR (panitumumab component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFOX and FOLFIRI are standard chemotherapy regimens for colorectal cancer that damage DNA and inhibit cell division. Panitumumab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) on cancer cells, blocking growth signals and preventing tumor progression. The combination leverages both direct cytotoxic effects and targeted growth inhibition to improve outcomes in colorectal cancer.
Approved indications
- Metastatic colorectal cancer, KRAS wild-type
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Skin rash (panitumumab-related)
- Mucositis
- Fatigue
Key clinical trials
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer (EARLY_PHASE1)
- Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer (PHASE2)
- Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC (PHASE2)
- Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy (PHASE2)
- Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients (PHASE2)
- The Sagittarius Trial (PHASE3)
- Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOLFOX/ FOLFIRI with panitumumab CI brief — competitive landscape report
- FOLFOX/ FOLFIRI with panitumumab updates RSS · CI watch RSS
- Dutch Colorectal Cancer Group portfolio CI